Article Text

Download PDFPDF
Cis-platin methotrexate and bleomycin (PMB) for carcinoma of the cervix: the influence of presentation and previous treatment upon response
  1. P. J. Hoskin1 and
  2. P. R. Blake1
  1. 1 Gynecology Unit, The Royal Marsden Hospital, Fulham Road, London, UK
  1. Address for correspondence: Dr P.R. Blake, Department of Radiotherapy and Oncology, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.


Combination chemotherapy using cisplatinum, methotrexate and bleomycin (PMB) has been evaluated in 60 patients with carcinoma of the cervix; 24 were treated neo-adjuvantly prior to definitive local treatment with radical radiotherapy and 36 were treated for recurrent or metastatic disease. The overall response rate was 40% with two complete responses. The response rate was 67% when the combination was used as a neoadjuvant treatment compared to only 27% with recurrent and metastatic disease. When relapse occurred in a previously irradiated site only 2/22 (9%) responded. This chemotherapy schedule was well-tolerated with no treatment-related deaths. It is concluded that PMB has a potential role as a neo-adjuvant treatment prior to radical radiotherapy in high risk patients with cervical cancer but alternative regimes are required for recurrent disease, particularly where there has been previous irradiation.

  • cervical cancer
  • chemotherapy
  • neo-adjuvant
  • metastatic recurrent.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.